Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B

ZHU Baoqiang; HU Qi; LIU Qiang; WANG Meiding; LONG Enwu

doi:10.6039/j.issn.1001-0408.2024.20.11

您当前的位置：

首页 >

文章列表页 >

Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B

更新时间：2024-10-25

- Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B
- ZHONGGUO YAOFANG Vol. 35, Issue 20, Pages: 2505-2511(2024)
- 作者机构：
  
  1.四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部/个体化药物治疗四川省重点实验室，成都　610072
  2.成都市双流区第一人民医院/四川大学华西空港医院药学部，成都　610200
  3.成都中医药大学附属医院药剂科，成都　610072
  4.西南医科大学药学院，四川泸州　646000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.20.11
  CLC： R975;R969.4
- Published：30 October 2024，
  
  Received：13 March 2024，
  
  Revised：29 August 2024，
- 稿件说明：
移动端阅览
朱宝强,胡琪,刘强等.多烯磷脂酰胆碱胶囊辅助治疗慢性乙型肝炎有效性的真实世界研究 ^Δ[J].中国药房,2024,35(20):2505-2511.

ZHU Baoqiang,HU Qi,LIU Qiang,et al.Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B[J].ZHONGGUO YAOFANG,2024,35(20):2505-2511.
朱宝强,胡琪,刘强等.多烯磷脂酰胆碱胶囊辅助治疗慢性乙型肝炎有效性的真实世界研究 ^Δ[J].中国药房,2024,35(20):2505-2511. DOI： 10.6039/j.issn.1001-0408.2024.20.11.

ZHU Baoqiang,HU Qi,LIU Qiang,et al.Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B[J].ZHONGGUO YAOFANG,2024,35(20):2505-2511. DOI： 10.6039/j.issn.1001-0408.2024.20.11.

摘要

目的

评价多烯磷脂酰胆碱胶囊（PPC）辅助治疗慢性乙型肝炎（CHB）的有效性。

方法

回顾性收集2017年1月1日－2022年12月31日于四川省医学科学院·四川省人民医院门诊就诊并诊断为CHB，使用保肝药物联合抗病毒药物治疗或单独使用抗病毒药物治疗，且在门诊进行长期随访的患者资料。通过倾向性评分匹配的方法平衡混杂因素后，比较真实医疗条件下PPC联合抗病毒方案对比单纯抗病毒治疗方案（即PPC+抗病毒组对比抗病毒组）、PPC+甘草酸二铵肠溶胶囊（DGC）联合抗病毒治疗方案对比DGC联合抗病毒治疗方案（即PPC+DGC+抗病毒组对比DGC+抗病毒组）治疗CHB的有效性。

结果

最终纳入在抗病毒治疗方案基础上使用保肝药物的CHB患者382例（使用DGC、PPC、两药联合方案的分别有221、63、98例）和单纯抗病毒治疗的患者400例。经倾向性评分匹配后，PPC+抗病毒组和抗病毒组患者各有47例；治疗后，PPC+抗病毒组患者的丙氨酸转氨酶（ALT）水平较同组治疗前和同期抗病毒组均显著降低（

＜0.05），而两组患者的ALT复常率比较差异无统计学意义（

＞0.05）。PPC+DGC+抗病毒组和DGC+抗病毒组患者各有74例；治疗后，两组患者的ALT水平均较同组治疗前显著降低，且PPC+DGC+抗病毒组患者的ALT水平显著低于同期DGC+抗病毒组，ALT复常率显著高于DGC+抗病毒组（

＜0.05）。

结论

在使用抗病毒药物治疗CHB的基础上，联合PPC辅助治疗具有明显的降酶优势；此外，与DGC联合抗病毒方案相比，DGC与PPC的双保肝药物联合抗病毒方案在保肝和降酶方面的效果更优。

Abstract

OBJECTIVE

To evaluate the effectiveness of Polyene phosphatidylcholine capsules （PPC） as adjuvant therapy for chronic hepatitis B （CHB）.

METHODS

Retrospective data were collected from the patients diagnosed with CHB， treated with hepatoprotective drugs combined with antiviral drugs or antiviral drugs alone， and underwent long-term follow-up in the outpatient department of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital from January 1， 2017 to December 31， 2022. After balancing confounding factors through propensity score matching， the effectiveness of PPC combined with antiviral therapy versus antiviral therapy alone （PPC+antiviral group versus antiviral group） and PPC+Diammonium glycyrrhizinate enteric-coated capsules （DGC） combined with antiviral therapy versus DGC combined with antiviral therapy （PPC+DGC+antiviral group versus DGC+antiviral group） as therapy for CHB were compared under real medical conditions.

RESULTS

Totally 382 patients with CHB who received hepatoprotective agents based on antiviral therapy （221， 63 and 98 patients who received DGC， PPC and combination therapy， respectively） and 400 patients who received antiviral therapy alone were ultimately included. After propensity score matching， there were 47 patients each in the PPC+antiviral group and the antiviral group， respectively； after treatment， the alanine transaminase （ALT） levels in the PPC+antiviral group were significantly reduced compared to before treatment and the antiviral group at the same time （

＜0.05）， while there was no statistically significant difference in the ALT normalization rate between the two groups （

＞0.05）. There were 74 patients each in the PPC+DGC+antiviral group and the DGC+antiviral group， respectively； after treatment， the ALT levels of patients in both groups were significantly reduced compared to before treatment， the ALT levels of PPC+DGC+antiviral group were significantly lower than those in the DGC+antiviral group at the same time， and the ALT normalization rate was significantly higher in the PPC+DGC+antiviral group than that in the DGC+antiviral group （

＜0.05）.

CONCLUSIONS

Based on using antiviral drugs to treat CHB， adjuvant therapy combined with PPC has a significant advantage in reducing liver enzymes； in addition， compared with the DGC combined antiviral regimen， the dual hepatoprotective drug of DGC and PPC combined with an antiviral regimen has better effects on liver protection and reduction of liver enzymes.

关键词

多烯磷脂酰胆碱胶囊保肝药物慢性乙型肝炎丙氨酸转氨酶倾向性评分匹配真实世界研究

Keywords

hepatoprotective drugchronic hepatitis Balanine transaminasepropensity score matchingreal-world study

references

睢淑莹，周一康，杨男，等. 中成药治疗慢性乙型肝炎的临床综合评价[J]. 中国药房，2023，34（5）：513-519.

SUI S Y，ZHOU Y K，YANG N，et al. Clinical comprehensive evaluation of Chinese patent medicine for the treatment of chronic hepatitis B[J]. China Pharm，2023，34（5）：513-519.

PATMORE L A，KATWAROE W K，VAN DER SPEK D，et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B[J]. Clin Gastroenterol Hepatol，2023，21（12）：3089-3096.e1.

陈梅，谢志红. 果糖注射液滴注对2型糖尿病合并慢性乙肝患者血糖的影响[J]. 糖尿病新世界，2022，25（14）：67-70.

CHEN M，XIE Z H. Effects of fructose injection on blood glucose in patients with type 2 diabetes mellitus complicated with chronic hepatitis B[J]. Diabetes N World，2022，25（14）：67-70.

XU J H，FAN Y N，YU Y Y，et al. A multicenter real-world study evaluating the hepatoprotective effect of polyene phosphatidylcholine against chronic hepatitis B[J]. Front Med，2022，9：842098.

尤红，王福生，李太生，等. 慢性乙型肝炎防治指南：2022年版 [J]. 实用肝脏病杂志，2023，26（3）：457-478.

YOU H，WANG F S，LI T S，et al. Guidelines for the prevention and treatment of chronic hepatitis B：version 2022[J]. J Pract Hepatol，2023，26（3）：457-478.

贺全浩，廖方通，彭粲杰，等. 机器人辅助腹腔镜前列腺癌根治术与腹腔镜前列腺癌根治术术后疗效对比分析：倾向性评分匹配队列研究[J]. 重庆医科大学学报，2023，48（8）：940-944.

HE Q H，LIAO F T，PENG C J，et al. A comparative analysis of the efficacy of robotic vs. laparoscopic radical prostatectomy：a propensity score matching cohort study[J]. J Chongqing Med Univ，2023，48（8）：940-944.

KANE L T，FANG T L，GALETTA M S，et al. Propensity score matching：a statistical method[J]. Clin Spine Surg，2020，33（3）：120-122.

王娟霞，陈馨悦，魏世博，等. 慢性乙型肝炎患者肝脏炎症程度预测模型的研究[J]. 中国实用内科杂志，2023，43（5）：390-395.

WANG J X，CHEN X Y，WEI S B，et al. Prediction model for inflammation degree in chronic hepatitis B patients：a retrospective study[J]. Chin J Pract Intern Med，2023，43（5）：390-395.

朱琪，刘银环，程变巧，等. 慢性乙型肝炎病毒携带者肝纤维化的相关因素分析[J]. 厦门大学学报（自然科学版），2021，60（5）：912-916.

ZHU Q，LIU Y H，CHENG B Q，et al. Analysis of factors related to liver fibrosis in chronic hepatitis B virus carriers[J]. J Xiamen Univ Nat Sci，2021，60（5）：912-916.

明艳. 慢性乙型肝炎病毒感染与代谢综合征研究进展[J]. 中华实用诊断与治疗杂志，2017，31（5）：500-502.

MING Y. Relationship between hepatitis B virus infection and metabolic syndrome[J]. J Chin Pract Diagn Ther，2017，31（5）：500-502.

乔月芹，李俊英，匡湧，等. 慢性乙型肝炎患者肝纤维化的代谢影响因素分析[J]. 中华医院感染学杂志，2016，26（17）：3889-3891.

QIAO Y Q，LI J Y，KUANG Y，et al. Metabolism-related influencing factors for liver fibrosis in patients with chronic hepatitis B[J]. Chin J Nosocomiology，2016，26（17）：3889-3891.

HU J，CHENG J J，TANG L D，et al. Virological basis for the cure of chronic hepatitis B[J]. ACS Infect Dis，2019，5（5）：659-674.

ZHONG S H，ZHANG T L，TANG L B，et al. Cytokines and chemokines in HBV infection[J]. Front Mol Biosci，2021，8：805625.

POPA G L，POPA M I. Oxidative stress in chronic hepatitis B：an update[J]. Microorganisms，2022，10（7）：1265.

FENG T T，YANG X Y，HAO S S，et al. TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization[J]. Immunol Res，2020，68（1）：28-38.

CAO M B，LI X L，ZHANG B Y，et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism[J]. Am J Transl Res，2016，8（5）：2325-2330.

IKEDA R，ISHII K，HOSHIKAWA Y，et al. Reactive oxygen species and NADPH oxidase 4 induced by transfor-ming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation[J]. Inflamm Res，2011，60（6）：597-604.

SUN Z G，ZHAO T T，LU N，et al. Research progress of glycyrrhizic acid on antiviral activity[J]. Mini Rev Med Chem，2019，19（10）：826-832.

RICHARD S A. Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and gly-cyrrhetinic acids[J]. Mediators Inflamm，2021，2021：6699560.

FAN J G，LI Y，YU Z，et al. Effectiveness and economic evaluation of polyene phosphatidyl choline in patients with liver diseases based on real-world research[J]. Front Pharmacol，2022，13：806787.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of camrelizumab combined with apatinib in first-line treatment of unresectable advanced hepatocellular carcinoma

真实世界研究的方法及其在临床研究中的应用

Study on Utilization Safety and Rationality of Sodium Tanshinone ⅡA Sulfonate Injection Based on “Real World ”

Related Author

ZHENG Xinkuo

XI Yalin

明丹丹

李军

许璇

李晶洁

陈孝

陈攀

Related Institution

Dept. of Pharmacy， Central Hospital of Dalian University of Technology （Dalian Municipal Central Hospital）

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰